EANS-Adhoc: Marseille-Kliniken AG / - Turnover growth of 5.6 % in first half of 2009/2010 totalling EUR 123.8 million - Earnings per share improve from EUR 0.08 to EUR 0.25 - Continued improvement of earnings expected
-------------------------------------------------------------------------------- ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------------
6-month report
08.02.2010
Berlin, 8 February 2010. Marseille-Kliniken AG (Prime Standard, ISIN DE 0007783003, MKA) increased operating turnover in the first half of the financial year 2009/2010 (1 July 2009 - 31 December 2009) by 5.6 % to EUR 123.8 million (previous year: EUR 117.2 million). Group net income before minority interests rose by EUR 2.3 million compared to the previous year - from EUR 0.8 million to EUR 3.1 million. Earnings per share was also up, reaching EUR 0.25 compared to EUR 0.08 in the previous year. EBIT/IFRS followed the trend, amounting to EUR 6.9 million compared to EUR 4.2 million in the previous year. EBITDAR/IFRS increased to EUR 35.0 million from EUR 31.7 million. Equity however decreased from EUR 79.5 million to EUR 65.0 million. This led to a decreased equity ratio of 29.5 % compared to 35.2 % last year. Debt however also fell from EUR 77.2 million to EUR 76.1 million. The positive development of these business figures show that the Group´s intense activities in the areas of marketing and cost optimisation continue to stabilise.
Adjusted Group net income according to DVFA/SG (IFRS) decrease from EUR 6.0 million in the first half of previous year to EUR 5.6 million. This corresponds to EUR 0.46 a share compared to EUR 0.49 last year. The lower earnings posted by the acute hospital in Büren and increased tax expenses were notable factors in this development. Adjusted EBITDAR meanwhile remained nearly unchanged at EUR 32.5 million after reaching EUR 32.7 million in the previous year. Adjusted EBIT amounted to EUR 8.6 million (previous year: EUR 9.0 million). Occupancy levels remained consistently high although capacity being increased by 287 beds. At the Group level, occupancy reached 92.8 % with 9,387 beds (previous year: 92.7 % with 9,100 beds).
As of the reporting date, capacity in the Care segment had increased from 7,771 beds to 8,058 beds as a result of expansions at the Waldkirch, Oberhausen and Bremerhaven sites. The Group´s entire capacity expansion is therefore only attributable to this segment. Turnover for the segment increased compared to the previous year from EUR 90.5 million to EUR 95.4 million. Two facilities negatively affected earnings according to DVFA/SG (IFRS) - bringing them down to EUR 4.7 million after amounting to EUR 4.9 million in the previous year. These facilities were still qualified as start-up facilities last year. The occupancy rate in Care amounted to 92.4 % after previously totalling 92.7 %.
Capacity in the Rehabilitation segment remained unchanged at 1,329 beds while turnover increased from EUR 26.6 million to EUR 28.4 million in the current reporting period. Earnings according to DVFA/SG (IFRS) fell slightly from EUR 1.1 million to EUR 0.9 million. The occupancy rate for the segment however rose from 92.5 % to 95.0 %.
Cost reduction measures will continue and Marseille-Kliniken is expecting increasing earnings from a project on optimising material costs in particular. The Group is also expecting further improvements on the income side, as it is now focussing on increasing occupancy levels at every facility after having completed a phase dedicated to opening new care facilities. An increase in occupancy is expected, in particular for the expansion facilities which had previously been responsible for negatively impacting earnings. Against this backdrop, the company expects the momentum gained in the first half of the year to remain throughout the coming two quarters.
For more detailed information, please visit the website www.marseille-kliniken.com to read the quarterly report.
End of the ad hoc release
end of announcement euro adhoc --------------------------------------------------------------------------------
Further inquiry note:
Marseille-Kliniken AG
Axel Hölzer
CEO
Alte Jakobstraße 79/80
10709 Berlin
Germany
Tel.: +49-(0)30 / 246 32-400
Fax: +49-(0)30 / 246 32-401
www.marseille-kliniken.com
;
Hillermann Consulting
Christian Hillermann
Investor Relations for Marseille-Kliniken AG
Poststraße 14/16
20354 Hamburg
Germany
Tel.: +49-(0)40 / 320 279-10
Fax: +49-(0)40 / 320 279-114
www.hillermann-consulting.de
Branche: Pharmaceuticals
ISIN: DE0007783003
WKN: 778300
Index: CDAX, Classic All Share, Prime All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Stuttgart / free trade
Düsseldorf / free trade
Hamburg / regulated dealing
Original-Content von: Marseille-Kliniken AG, übermittelt durch news aktuell